Q1 Earnings Estimate for Immunome Issued By Lifesci Capital

Immunome, Inc. (NASDAQ:IMNM) – Stock analysts at Lifesci Capital issued their Q1 2025 EPS estimates for shares of Immunome in a report issued on Tuesday, March 11th. Lifesci Capital analyst C. Zhu forecasts that the company will earn ($0.61) per share for the quarter. Lifesci Capital currently has a “Outperform” rating and a $20.00 price target on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome’s Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.

IMNM has been the subject of several other research reports. Wedbush restated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research report on Monday. Piper Sandler dropped their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome currently has an average rating of “Buy” and an average price target of $27.17.

Immunome Stock Performance

Shares of NASDAQ:IMNM opened at $9.21 on Thursday. The company has a market cap of $734.75 million, a PE ratio of -1.14 and a beta of 1.93. Immunome has a 52 week low of $8.39 and a 52 week high of $26.70. The firm has a 50 day simple moving average of $10.06 and a 200 day simple moving average of $11.87.

Insider Buying and Selling at Immunome

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were bought at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now directly owns 669,636 shares in the company, valued at $5,189,679. This trade represents a 28.87 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its stake in shares of Immunome by 217.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock worth $6,469,000 after purchasing an additional 302,916 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Immunome by 48.1% during the 3rd quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after purchasing an additional 237,497 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock worth $17,657,000 after purchasing an additional 144,557 shares during the last quarter. Magnus Financial Group LLC increased its stake in shares of Immunome by 107.8% during the 4th quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock worth $569,000 after purchasing an additional 27,777 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in shares of Immunome by 22.2% during the 3rd quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after buying an additional 85,580 shares during the period. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.